title: Triple subconjunctival bevacizumab injection for early corneal recurrent pterygium: one-year follow-up.
abstract: OBJECTIVE
  The aim of the study was to evaluate the effect of 3 subconjunctival bevacizumab injections in patients with an early corneal pterygium recurrence.
  
  
  METHODS
  This study was a nonrandomized single center trial. Patients with an early corneal pterygium recurrence were selected. All patients received 3 subconjunctival bevacizumab (2.5 mg/0.1 mL) injections (basal, 2 and 4 weeks) in the recurrence area of the pterygium. The corneal and corneal-conjunctival neovascularization areas and the corneal opacification area of each pterygium were determined using digital slit lamp pictures.
  
  
  RESULTS
  Thirty-eight patients were enrolled into the study; all patients were injected within 3 months of the diagnosed pterygium recurrence. Interestingly, the bevacizumab injections had a significant effect (P<0.05) on the reduction of corneal, corneal-conjunctival area of neovascularization determined as pixels and on the corneal opacification area determined as mm(2) when comparing the basal values, to the values obtained after 15 days, 1 month, 3 months, 6 months, and 12 months after injections.
  
  
  CONCLUSIONS
  The vascularized area in all recurrent pterygia and the corneal opacification area with this triple regimen of subconjunctival bevacizumab injections were reduced, which remained until the end of the study. These results suggest that bevacizumab subconjunctival injections could be useful to treat recurrent pterygium.
authors.affiliation: 1 Research Unit, Institute of Ophthalmology Conde de Valenciana Foundation, Colonia Obrera, Mexico City, Mexico.
authors.forename: Angel
authors.initials: A
authors.lastname: Nava-Castañeda
authors.forename: Isabel
authors.initials: I
authors.lastname: Ulloa-Orozco
authors.forename: Lilia
authors.initials: L
authors.lastname: Garnica-Hayashi
authors.forename: Joaquín
authors.initials: J
authors.lastname: Hernandez-Orgaz
authors.forename: Maria Carmen
authors.initials: MC
authors.lastname: Jimenez-Martinez
authors.forename: Yonathan
authors.initials: Y
authors.lastname: Garfias
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D016510:Corneal Neovascularization / Q000188:drug therapy; D003318:Corneal Opacity / Q000188:drug therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D056965:Injections, Intraocular; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011625:Pterygium / Q000188:drug therapy* / Q000473:pathology; D012008:Recurrence
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab